We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-2.82%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.01B
AUM Growth
-$1.6B
Cap. Flow
-$1.27B
Cap. Flow %
-42.02%
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
23

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$89.8M
2
BDX icon
Becton Dickinson
BDX
+$70.5M
3
ZTS icon
Zoetis
ZTS
+$66.8M
4
MRK icon
Merck
MRK
+$64.8M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$60.5M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$218M
2
ARGX icon
argenx
ARGX
+$127M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$125M
4
BSX icon
Boston Scientific
BSX
+$113M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$100M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNAD
101
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
– –
-200,000
Closed -$2.01M
DNAB
102
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
– –
-200,000
Closed -$2.01M
RXDX
103
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-204,000
Closed -$22.4M
PANA
104
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
– –
-500,000
Closed -$5.03M
MSACW
105
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
– –
-57,770
Closed -$5.2K
MSAC
106
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
– –
-520,000
Closed -$5.24M
1 2 3 4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2023 Portfolio in Review

As of Q1 2023, Avidity Partners Management held 106 positions worth $3.01B, down 35% from $4.62B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $1.27B in Q1 2023, closing 23 positions and reducing 41 holdings. Its most notable exit was United Therapeutics, an estimated $218M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier, followed by Financials.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $97.9M.

  • Avidity Partners Management's largest Q1 2023 buy was Regeneron Pharmaceuticals: 119,100 shares worth $97.9M.
  • Avidity Partners Management added most to Bio-Rad Laboratories Class A in Q1 2023, an estimated $60.5M increase.
  • Avidity Partners Management's biggest Q1 2023 reduction was argenx, cutting an estimated $127M.
  • Avidity Partners Management fully exited United Therapeutics in Q1 2023, selling an estimated $218M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $3.01B portfolio in Q1 2023.
  • Avidity Partners Management opened 21 new positions and closed 23 in Q1 2023.
  • Avidity Partners Management's portfolio value fell 35% quarter-over-quarter to $3.01B.

Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.